Advanced Lung Cancer
Conditions
Keywords
neutrophil to lymphocyte ratio (NLR), immunomodulator
Brief summary
The main objective of this study is to evaluate the change of neutrophil to lymphocyte ratio (NLR) after 6-week treatment of immune checkpoint inhibitors (ICIs) with or without immunomodulatory drugs and recognize the effect of post-treatment NLR and overall survival in advanced lung cancer patients by retrospective review.
Detailed description
In recent years, the therapeutic strategies for lung cancer have been enriched with small molecular targeted therapy and immunotherapy. In this retrospective study, we will observe the change in NLR and explore its possible association with survival among advanced lung cancer patients receiving Immune checkpoint inhibitors (ICIs) with and without such immuno-modulator, Astragalus Polysaccharide Injection. It can be used to understand the relationship between NLR values and the survival rate of lung cancer patients after ICIs treatment. Physicians can refer to this result to give patients the suitable treatment recommendations.
Interventions
None listed
Sponsors
Chung Shan Medical University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Aged 20 years and older. * Patients who have been given a diagnosis of lung cancer. * Previously advanced lung cancer patients first treated with ICIs from Oct 1, 2015 to Oct 31, 2019.
Exclusion criteria
* Patients who have no hematological laboratory data available at baseline (within 3 days prior to ICI treatment) and the 6th week (± 2 weeks) after ICI treatment initiation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Neutrophil to lymphocyte ratio (NLR) | Baseline, 4~8 week |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival (OS) | 4 years |
Countries
Taiwan
Outcome results
None listed